Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence.

Ann Neurol · 2026 · PMC12946588 · PMID 40919837

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Controlled trials of rituximab are limited to a single phase II trial in RRMS in which magnetic resonance imaging (MRI) activity at 6 months after a single dose was the primary end point, and in PPMS, a single phase II/III trial revealed a nonsignificant trend for reduced CDP.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.